

Approved



Rwanda
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		260,000		260,000	0	260,000
USAID		37,597,621		37,597,621	262,496	37,860,117
DOD		2,803,777		2,803,777	0	2,803,777
HHS/CDC	1,440,625	29,732,125		31,172,750	0	31,172,750
State/PRM		216,717		216,717	0	216,717
State/SGAC		3,805,966		3,805,966	0	3,805,966
Total	1,440,625	74,416,206	0	75,856,831	262,496	76,119,327

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						Total
	State	DOD	HHS/CDC	State/SGAC	State/PRM	USAID	
CIRC		1,242,974	1,035,278	482,296	0	1,918,268	4,678,816
HBHC	12,500	64,610	1,082,658	389,263	12,075	773,720	2,334,826
HKID		0	0	0	0	7,130,058	7,130,058
HLAB		0	424,766	0	0	89,387	514,153
HMBL		0	0	0	0	0	0
HMIN		0	0	0	0	0	0
HTXD		0	0	389,263	0	14,678,903	15,068,166
HTXS	12,500	837,065	14,196,250	391,085	59,873	5,376,538	20,873,311
HVAB		0	0	0	0	1,096,231	1,096,231
HVCT		299,590	1,780,789	100,660	21,494	1,796,024	3,998,557
HVMS	185,000	62,045	3,796,173			1,621,453	5,664,671
HVOP	12,500	206,034	1,185,378	784,947	29,192	1,540,359	3,758,410

Approved



HVSI	12,500	32,045	1,839,267	0	0	268,906	2,152,718
HVTB		5,341	993,610	389,263	5,610	0	1,393,824
IDUP		0	0	0	0	0	0
MTCT		20,905	1,947,566	100,663	68,116	6,925	2,144,175
OHSS	12,500	0	825,023	0	0	576,590	1,414,113
PDCS	12,500	13,913	1,046,629	389,263	9,927	639,665	2,111,897
PDTX		19,255	1,019,363	389,263	10,430	84,594	1,522,905
	260,000	2,803,777	31,172,750	3,805,966	216,717	37,597,621	75,856,831



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	1,668,671
HKID	7,055,782
HVTB	982,990
PDCS	1,643,352
Total Technical Area Planned Funding:	11,350,795

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	435,278
HVSI	1,547,237
OHSS	1,235,618
Total Technical Area Planned Funding:	3,218,133

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	4,652,316
HMBL	0
HMIN	0
HVAB	1,096,231
HVCT	3,850,268
HVOP	3,605,396
IDUP	0
MTCT	2,095,152
Total Technical Area Planned Funding:	15,299,363

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	14,870,563
HTXS	20,123,034
PDTX	1,033,078
Total Technical Area Planned Funding:	36,026,675



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	99 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	105,841
	Number of new ANC and L&D clients	106,911
	By Age (Denominator): 10-14	74
	By Age (Denominator): <15-19	5,204
	By Age (Denominator): 20-24	27,316
	By Number of known positives: 10-14	2
	By Number of known positives: 15-19	51
	By Number of known positives: 20-24	253
	By Number of new positives: 10-14	1
	By Number of new positives: 15-19	43
	By Number of new positives: 20-24	167
	By Number of new negative: 10-14	15
	By Number of new negative: 15-19	4,557
	By Number of new negative: 20-24	25,944
	By Number of new negative: 50+	4
By Age (Numerator): 10-14	18	
By Age (Numerator): 15-19	4,651	



	By Age (Numerator): 20-24	26,351
	By Age (Numerator): 50+	4
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	19,297
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	18,430
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	18,430
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	18,160
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	559
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	18,086
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	135
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	559
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	17,943
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	125
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	559
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	17,943



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	125
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	559
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	17,815
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	125
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	18,787
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	18,640
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	18,637
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	18,510
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,248
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	105,841
	New on ART	718



	Already on ART at beginning of current pregnancy	2,530
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	107,234
	By Age: 10-14	5,997
	By Age: 15-19	59,592
	By Age: 20-24	17,094
	By Age: 25-29	6,571
	By circumcision technique: Surgical VMMC	75,064
	By circumcision technique: Device-based VMMC	32,168
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	9,592
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	7,196
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,194
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,800
	Male 20-24	21
	Male 50+	4
	Female 15-19	85



	Female 20-24	371
	Female 50+	4
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	406
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	30
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	308
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	95
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	313
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	57
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	94
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	9
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	69,622
	Age/sex: 15-19 Male	1,953
	Age/sex: 20-24 Male	6,869
	Age/sex: 50+ Male	1,545
	Age/sex: 10-14 Female	9,098
	Age/sex: 15-19 Female	17,775



	Age/sex: 20-24 Female	12,984
	Age/sex: 50+ Female	25
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	3,356
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,481
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	3,293
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,914
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,789
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3,263
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,601
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,664
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,777
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level	1,440



	HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,337
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,784
	Total number of registered new and relapsed TB cases, during the reporting period.	1,784
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	81
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,083
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	54



	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	611
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	70
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,078
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	49
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	600
HTS_SELF_DSD	HTS_SELF_N_DSD	88,129
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	4,710
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	4,283
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	4,591
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	4,283



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	4,710
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	5,892
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	5,384
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	1,876
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	914
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	4,283
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	41
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	4,283
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	915
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	4,283
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	898
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	4,283
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female,	913



	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	4,283
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	899
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	4,283
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	4,709
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	4,283
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	4,591
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	4,283
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	4,283
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	31,541
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	56,588
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	17,126
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Unassisted	389
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,042,559



	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,400
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	16
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,396
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	16
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,624
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	23
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,262
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	12
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	11,858
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	59
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,657
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	17
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3,990
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	40
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,358
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	50
	Service Delivery Point (Facility) Inpatient: <1, Negative	559



	Service Delivery Point (Facility) Inpatient: <1, Positive	3
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,640
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	17
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,676
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	44
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,006
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	4,785
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	171
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	3,504
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	16
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	12,705
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	375
	Service Delivery Point (Community) Mobile Testing: 20-24, Male,	7,316



	Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	287
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	2,704
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	140
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,896
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	46
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,808
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	7
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,963
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	13
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	12,318
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	74
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	12,433
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	38



Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	25,970
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	286
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	28,640
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	153
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	17,578
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	156
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	15,209
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	183
Service Delivery Point (Facility)Other PITC: <1, Negative	1,162
Service Delivery Point (Facility) Other PITC: <1, Positive	4
Service Delivery Point (Facility) Other PITC: 1-9, Negative	9,709
Service Delivery Point (Facility) Other PITC: 1-9, Positive	29
Service Delivery Point (Facility) Pediatric : <5 Negative	8,587
Service Delivery Point (Facility) Pediatric : <5 Positive	40
Service Delivery Point (Facility) TB: 10-14, Female, Negative	31
Service Delivery Point (Facility) TB: 10-14, Female, Positive	1



	Service Delivery Point (Facility) TB: 10-14, Male, Negative	31
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	54
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	52
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	90
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	92
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10
	Service Delivery Point (Facility) TB: 50+, Female, Negative	147
	Service Delivery Point (Facility) TB: 50+, Female, Positive	9
	Service Delivery Point (Facility) TB: 50+, Male, Negative	141
	Service Delivery Point (Facility) TB: 50+, Male, Positive	12
	Service Delivery Point (Facility) TB: <1, Negative	1
	Service Delivery Point (Facility) TB: 1-9, Negative	30
	Service Delivery Point (Facility) TB: 1-9, Positive	1



	Service Delivery Point (Facility) VMMC: 15-19, Negative	31,039
	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
	Service Delivery Point (Facility) VMMC: 20-24, Negative	8,916
	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
	Service Delivery Point (Facility) VMMC: 50+, Negative	115
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,349
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	41
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,170
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	21
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,482
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	107
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,328
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	55
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,681
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	364
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	966
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	277



Service Delivery Point (Facility) Index: 50+, Female, Negative	605
Service Delivery Point (Facility) Index: 50+, Female, Positive	153
Service Delivery Point (Facility) Index: 50+, Male, Negative	462
Service Delivery Point (Facility) Index: 50+, Male, Positive	140
Service Delivery Point (Facility) Index: <1, Negative	568
Service Delivery Point (Facility) Index: <1, Positive	40
Service Delivery Point (Facility) Index: 1-9, Negative	3,675
Service Delivery Point (Facility) Index: 1-9, Positive	52
By Key Population: FSW, Negative	14,738
By Key Population: FSW, Positive	797
By Key Population: MSM, Negative	1,401
By Key Population: MSM, Positive	24
By Key Population: People in prisons and other enclosed settings, Negative	3,403
By Key Population: People in prisons and other enclosed settings, Positive	39
By Key Population: TG, Negative	6
Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	9
Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	37
Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	33



	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	17
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	56
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	33
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	112
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	33
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	6
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	11
	Service Delivery Point (Community) Index Mod: 1-9, Negative	84
	Service Delivery Point (Community) Index Mod: 1-9, Positive	5
	Service Delivery Point (Facility) ANC: 10-14, Negative	55
	Service Delivery Point (Facility) ANC: 10-14, Positive	2
	Service Delivery Point (Facility) ANC: 15-19, Negative	4,553
	Service Delivery Point (Facility) ANC: 15-19, Positive	41
	Service Delivery Point (Facility) ANC: 1-9, Negative	5
	Service Delivery Point (Facility)	25,119



	ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	179
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	4,590
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	19
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	10,570
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	18
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	15,575
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	135
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	27,585
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	30
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	32,316
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	433
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	30,773
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	155
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	13,391
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	255
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	13,345
	Service Delivery Point (Facility)	260



VCT: 50+, Male, Positive	
Service Delivery Point (Facility) VCT: <1, Negative	424
Service Delivery Point (Facility) VCT: <1, Positive	10
Service Delivery Point (Facility) VCT: 1-9, Negative	3,508
Service Delivery Point (Facility) VCT: 1-9, Positive	30
Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	5,151
Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	125
Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	2,776
Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	25
Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	17,226
Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	286
Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	3,178
Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	32
Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	1,816
Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	42
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	1,232
Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	88
HTS_TST_N_DSD_EW_Age_Sex_	13



	Result 10-14, Female, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Negative	13
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	13
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Negative	9
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Negative	9
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	9
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_	1



	Result 30-34, Male, Positive	
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Negative	16
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Female, Negative	6
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Male, Negative	6
	HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Male, Positive	1
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Female, Negative	890
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Female, Positive	343
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Male, Negative	841
	HTS_TST_N_DSD_Index_Age_Sex_ Result 25-29, Male, Positive	319
	HTS_TST_N_DSD_Index_Age_Sex_	812



x_Result 30-34, Female, Negative	
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	314
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	759
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	287
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	757
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	316
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	740
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	238
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	776
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	230
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	713
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	204
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	5,257
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	43
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	3,003
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	25
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	5,367
HTS_TST_N_DSD_Inpat_Age_Sex	43



	_Result 30-34, Female, Positive	
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	3,003
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	28
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	5,366
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	44
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	3,003
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	25
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	5,366
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	43
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	3,087
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	16
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	5,682
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	287
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	6,192
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	295
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	5,774



HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	174
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	4,011
HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	295
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	3,885
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	287
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	4,209
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	237
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	5,601
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	199
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	5,476
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	149
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,361
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	4
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	57



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	57
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	57
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	57
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	57
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	51
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	51
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	3
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	51



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	3
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	28,267
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	192
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	19,043
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	266
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	28,267
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	192
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	19,043
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	266
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	27,775
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	192
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	18,283
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	275
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	26,981



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	213
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	13,423
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	291
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	18,514
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	128
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	18,525
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	123
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	17,857
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	122
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	17,847
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	122
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	13
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	13



	HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Female, Negative	14
	HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Male, Negative	14
	HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Negative	16
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Negative	16
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	17



	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	17
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	12
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	1
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	12
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	1
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	78
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	12
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	78
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Positive	12
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Negative	78
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Positive	12



HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Negative	78
HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	12
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	80
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	12
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	76
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	12
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	73
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	11
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	62
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	11
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	17,988
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	261
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	18,298
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	262
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	18,301
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	268
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	18,145



HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	261
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	17,851
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	268
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	18,786
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	262
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	18,786
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	268
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	18,160
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	261
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	3,511
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	178
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	4,916
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	178
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	6,321
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	106



HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	5,621
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	178
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	4,917
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	178
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	4,215
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	141
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	4,917
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	125
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	4,215
HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	88
HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	3,709
HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	21
HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	7,652
HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	47
HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	5,891



	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Positive	36
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Negative	1,166
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Positive	8
GEND_GBV_DSD	Number of people receiving post-GBV care	7,796
	By type of service: Sexual Violence (Post-Rape Care)	5,691
	By PEP service provision (related to sexual violence services provided)	2,097
	<10, Female, Physical and/or Emotional Violence	112
	<10, Female, Sexual Violence (Post-Rape Care)	1,290
	<10, Male, Physical and/or Emotional Violence	141
	<10, Male, Sexual Violence (Post-Rape Care)	122
	10-14, Female, Physical and/or Emotional Violence	75
	10-14, Female, Sexual Violence (Post-Rape Care)	702
	10-14, Male, Physical and/or Emotional Violence	129
	10-14, Male, Sexual Violence (Post-Rape Care)	33
	15-19, Female, Physical and/or Emotional Violence	120
	15-19, Female, Sexual Violence (Post-Rape Care)	2,243
	15-19, Male, Physical and/or	53



	Emotional Violence	
	15-19, Male, Sexual Violence (Post-Rape Care)	30
	20-24, Female, Physical and/or Emotional Violence	309
	20-24, Female, Sexual Violence (Post-Rape Care)	296
	20-24, Male, Physical and/or Emotional Violence	33
	20-24, Male, Sexual Violence (Post-Rape Care)	7
	50+, Female, Physical and/or Emotional Violence	92
	50+, Female, Sexual Violence (Post-Rape Care)	16
	50+, Male, Physical and/or Emotional Violence	37
	50+, Male, Sexual Violence (Post-Rape Care)	5
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Female, Physical and/or Emotional Violence	178
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	275
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Male, Physical and/or Emotional Violence	79
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	9
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 30-34, Female, Physical and/or Emotional Violence	178



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	275
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	79
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	9
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	178
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	199
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	79
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	9
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	137
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	160
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	79
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	9
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs	116,266



	for children and families affected by HIV/AIDS	
	Age/Sex: 10-14 Male	13,522
	Age/Sex: 15-17 Male	12,896
	By: Age/sex: Male 18-24	5,562
	By: Age/sex: Male 25+	12,833
	Age/Sex: 10-14 Female	17,724
	Age/Sex: 15-17 Female	15,568
	By: Age/sex: 18-24 Female	7,634
	By: Age/sex: 25+ Female	17,949
	Sum of Age/Sex disaggregates	59,710
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,250
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	9,829
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3,345
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	5,407
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	5,584
	Required only for DREAMS countries - By service, age and sex: Social Protection Female	14,417



	15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	7,999
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,923
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	4,654
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	5,584
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	14,417
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	7,999
	Age/Sex: <1	47
	Age/Sex: 1-9	13,912
	Program Completion: Active	104,702
	Program Completion: Graduation	11,564
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	63 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	73,669



	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	116,266
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	460
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	271
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
	Aggregated Age/Sex: Female 15+ (Numerator: The number of	184

	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	126,617
	Denominator: By Aggregated Age/Sex: <15, Female	2,940
	Denominator: By Aggregated Age/Sex: <15, Male	2,837
	Denominator: By Aggregated Age/Sex:15+, Female	75,525
	Denominator: By Aggregated Age/Sex:15+, Male	45,317
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,862
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,003
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	863
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months	3,255



	of birth during the reporting period	
	By infants who received a virologic test within 2 months of birth	3,077
	By infants who received their first virologic HIV test between 2 and 12 months of age	178
	Sum of Infant Age disaggregates	3,255
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	109,623
	Age/Sex: 15-19 Male	1,576
	Age/Sex: 15-19 Female	2,068
	Age/Sex: <1	32
	Age/Sex: <1-9	2,005
	Age/Sex: 10-14 Male	1,432
	Age/Sex: 10-14 Female	1,433
	Age/Sex: 20-24 Male	2,223
	Age/Sex: 50+ Male	11,387
	Age/Sex: 20-24 Female	4,732
	Age/Sex: 50+ Female	13,480
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	11,041
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	6,245
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	11,041
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	6,245
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	11,041
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	6,245
TX_CURR_N_DSD_Age_Sex_HIV	11,041	



	Status 40-49, Female, Positive	
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	6,245
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,997
	Age/Sex: 15-19 Male	254
	Age/Sex: 15-19 Female	283
	Sum of Age/Sex disaggregations	537
	Age/Sex: 1-9	211
	Age/Sex: 10-14 Male	142
	Age/Sex: 10-14 Female	139
	Age/Sex: 20-24 Male	300
	Age/Sex: 50+ Male	1,601
	Age/Sex: 20-24 Female	687
	Age/Sex: 50+ Female	1,773
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	1,925
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	958
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	1,925
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	958
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	1,925
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	958
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	1,925
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	958
TX_NEW_DSD	Number of adults and children	13,322



	newly enrolled on antiretroviral therapy (ART)	
	By Age/Sex: <1	50
	By Age/Sex: 1-9	90
	By Age/Sex: 10-14 Male	69
	By Age/Sex: 15-19 Male	152
	By Age/Sex: 20-24 Male	581
	By Age/Sex: 50+ Male	721
	By Age/Sex: 10-14 Female	189
	By Age/Sex: 15-19 Female	546
	By Age/Sex: 20-24 Female	1,526
	By Age/Sex: 50+ Female	728
	Pregnancy status	1,196
	Breastfeeding status	233
	FSW	152
	MSM	4
	People in prisons and other enclosed settings	185
	By Key populations: People who inject drugs (PWID)	4
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	1,221
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	972
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	1,221
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	972
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	1,221
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	968
	TX_NEW_N_DSD_Age_Sex_HIVS	1,221



	tatus 40-49, Female, Positive	
	TX_NEW_N_DSD_Age_Sex_HIVS	968
	tatus 40-49, Male, Positive	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	749
	By Age/Sex: <1	1
	By Age/Sex: 1-9	3
	By Age/Sex: 10-14 Male	26
	By Age/Sex: 15-19 Male	30
	By Age/Sex: 20-24 Male	38
	By Age/Sex: 50+ Male	3
	By Age/Sex: 10-14 Female	6
	By Age/Sex: 15-19 Female	19
	By Age/Sex: 20-24 Female	94
	By Age/Sex: 50+ Female	11
	Sum of Age/Sex disaggregates	227
	Pregnancy status	20
	Breastfeeding status	1
	FSW	142
	MSM	11
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	51
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	106
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	48
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	108
TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	46	
TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	93	



	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	47
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	89
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	96,617
	Denominator: Indication: Routine	77,293
	Denominator: Indication: Targeted	19,322
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	4,835
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,812
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	4,837
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,827
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	19,293
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	19,343
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	19,308
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	19,305



TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	95 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,829
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	13,483
	Numerator by Status: Pregnant	720
	Numerator by Status: Breastfeeding	60
	Denominator by Status: Pregnant	810
	Denominator by Status: Breastfeeding	73
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	191
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,815
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	184



	<p>Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	<p>7,629</p>
	<p>Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>196</p>
	<p>Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>5,084</p>
	<p>Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>192</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and</p>	<p>7,988</p>

Approved



	those lost to follow-up)	
--	--------------------------	--



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10981	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	216,717
13598	JHPIEGO	University	U.S. Department of Defense	GHP-State	970,398
16857	African Evangelistic Enterprise	FBO	U.S. Agency for International Development	GHP-State	1,165,810
16858	Caritas Rwanda	FBO	U.S. Agency for International Development	GHP-State	1,403,974
16859	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	332,189
16860	François Xavier Bagnoud	NGO	U.S. Agency for International Development	GHP-State	1,013,039
17616	CHF International	NGO	U.S. Agency for International Development	GHP-State	5,665,423
17618	Society for Family Health	NGO	U.S. Department of Defense	GHP-State	496,362
17619	Emory University	University	U.S. Department of Health and Human	GHP-State	2,210,561



			Services/Centers for Disease Control and Prevention		
17623	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	16,011,222
17625	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,389,218
18418	Alliance for Health Communities	NGO	U.S. Department of Defense	GHP-State	1,072,017
18422	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	714,797
18426	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	25,427,272
18432	Public Health Institute	NGO	U.S. Agency for International Development	GHP-State	1
70277	TBD	TBD	Redacted	Redacted	Redacted
70278	TBD	TBD	Redacted	Redacted	Redacted

Approved



70279	TBD	TBD	Redacted	Redacted	Redacted
70280	TBD	TBD	Redacted	Redacted	Redacted
70281	TBD	TBD	Redacted	Redacted	Redacted
70282	TBD	TBD	Redacted	Redacted	Redacted
70283	TBD	TBD	Redacted	Redacted	Redacted
70284	TBD	TBD	Redacted	Redacted	Redacted
70285	TBD	TBD	Redacted	Redacted	Redacted
70286	TBD	TBD	Redacted	Redacted	Redacted
70513	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10981	Mechanism Name: UNHCR
Funding Agency: State/PRM	Procurement Type: Grant
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 216,717	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 216,717	
Funding Source	Funding Amount
GHP-State	216,717

Cross-Cutting Budget Attribution(s)

Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID: 10981
Mechanism Name: UNHCR



Prime Partner Name: United Nations High Commissioner for Refugees		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	12,075
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	5,610
Strategic Area	Budget Code	Planned Amount
Care	PDCS	9,927
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	21,494
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	29,192
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	68,116
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	59,873
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	10,430

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	45
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,093
PMTCT_ART_DSD	New on ART	5
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	40



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,093
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,112
PMTCT_STAT_DSD	By Age (Denominator): 10-14	2
PMTCT_STAT_DSD	By Age (Denominator): <15-19	106
PMTCT_STAT_DSD	By Age (Denominator): 20-24	571
PMTCT_STAT_DSD	By Number of known positives: 20-24	3
PMTCT_STAT_DSD	By Number of new positives: 20-24	1
PMTCT_STAT_DSD	By Number of new negative: 15-19	93
PMTCT_STAT_DSD	By Number of new negative: 20-24	526
PMTCT_STAT_DSD	By Age (Numerator): 15-19	94
PMTCT_STAT_DSD	By Age (Numerator): 20-24	531
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	362
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	357
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	357
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	357
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	354
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	354
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	354



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	354
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	363
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,005
PP_PREV_DSD	Age/sex: 10-14 Female	750
PP_PREV_DSD	Age/sex: 15-19 Female	2,005
PP_PREV_DSD	Age/sex: 20-24 Female	2,250
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,005
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	139
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	139
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	1



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	219
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	242



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	10



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	31
HTC_TST_DSD	By Key Population: FSW, Negative	302
HTC_TST_DSD	By Key Population: FSW, Positive	12
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	186
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	89



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	489
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	390
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	338
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	366
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	193
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	8



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	22



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	216
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	337
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	348
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	332
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	322
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	193
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	193
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	193
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	198

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	17
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	17
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1



PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	35
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	25
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	10
PMTCT_EID_DSD	Sum of Infant Age disaggregates	35
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	485
TX_CURR_DSD	Age/Sex: 15-19 Male	6
TX_CURR_DSD	Age/Sex: 15-19 Female	10
TX_CURR_DSD	Sum of age/sex disaggregates	16
TX_CURR_DSD	Age/Sex: <1-9	13
TX_CURR_DSD	Age/Sex: 10-14 Male	11
TX_CURR_DSD	Age/Sex: 10-14 Female	10
TX_CURR_DSD	Age/Sex: 20-24 Male	5
TX_CURR_DSD	Age/Sex: 50+ Male	53
TX_CURR_DSD	Age/Sex: 20-24 Female	22
TX_CURR_DSD	Age/Sex: 50+ Female	62
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	46
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	25
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	46
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	25
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	46
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	25
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	46



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	25
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	46
TX_NEW_DSD	By Age/Sex: 20-24 Male	2
TX_NEW_DSD	By Age/Sex: 50+ Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	2
TX_NEW_DSD	By Age/Sex: 20-24 Female	5
TX_NEW_DSD	By Age/Sex: 50+ Female	3
TX_NEW_DSD	Sum of Age/Sex disaggregates	15
TX_NEW_DSD	Pregnancy status	5
TX_NEW_DSD	People in prisons and other enclosed settings	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	562
TX_PVLS_DSD	Denominator: Indication: Routine	450
TX_PVLS_DSD	Denominator: Indication: Targeted	112



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	28
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	28
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	28
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	28
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	113
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	111
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	112
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	113
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	40
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	46
TX_RET_DSD	Numerator by Status: Pregnant	2
TX_RET_DSD	Denominator by Status: Pregnant	2
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	24

	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
HTS_SELF_DSD	HTS_SELF_N_DSD	1,168
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	70



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	83
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	59



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	434
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	734
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	234
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1,150
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	32
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	32
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	688
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	397
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	13
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	6
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	5

Implementing Mechanism Details

Mechanism ID: 13598	Mechanism Name: JHPIEGO Rwanda
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 970,398	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 970,398	
Funding Source	Funding Amount
GHP-State	970,398



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13598 Mechanism Name: JHPIEGO Rwanda Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	970,398
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	42,248
VMMC_CIRC_DSD	By Age: 10-14	3,485
VMMC_CIRC_DSD	By Age: 15-19	20,551
VMMC_CIRC_DSD	By Age: 20-24	5,849
VMMC_CIRC_DSD	By Age: 25-29	1,906
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	29,885
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	31,791
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	29,573
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	12,674
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	5,577
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	4,183
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	697
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	80
TX_NEW_TA	By Age/Sex: 10-14 Male	2
TX_NEW_TA	By Age/Sex: 15-19 Male	8
TX_NEW_TA	By Age/Sex: 20-24 Male	19
TX_NEW_TA	Sum of Age/Sex disaggregates	29
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	19
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	20
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	4



Implementing Mechanism Details

Mechanism ID: 16857	Mechanism Name: Ubaka Ejo
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Evangelistic Enterprise	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,165,810	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,165,810	
Funding Source	Funding Amount
GHP-State	1,165,810

Cross-Cutting Budget Attribution(s)

Gender: GBV	35,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	813,596
Water	46,000

Budget Code Information

Mechanism ID: 16857



Mechanism Name: Ubaka Ejo		
Prime Partner Name: African Evangelistic Enterprise		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	711,332
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	227,239



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	227,239
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,633
PP_PREV_DSD	Age/sex: 15-19 Male	56
PP_PREV_DSD	Age/sex: 20-24 Male	169
PP_PREV_DSD	Age/sex: 10-14 Female	1,912
PP_PREV_DSD	Age/sex: 15-19 Female	2,250
PP_PREV_DSD	Age/sex: 20-24 Female	1,237



PP_PREV_DSD	Sum of Age/Sex disaggregates	5,624
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,581
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,188
OVC_SERV_DSD	Age/Sex: 15-17 Male	2,423
OVC_SERV_DSD	By: Age/sex: Male 18-24	520
OVC_SERV_DSD	By: Age/sex: Male 25+	1,050
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,473
OVC_SERV_DSD	Age/Sex: 15-17 Female	3,257
OVC_SERV_DSD	By: Age/sex: 18-24 Female	835
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,835
OVC_SERV_DSD	Sum of Age/Sex disaggregates	9,341
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,083
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,874
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	751
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,082
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,708
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,625
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,625
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,082
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,708
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,625



OVC_SERV_DSD	Age/Sex: <1	6
OVC_SERV_DSD	Program Completion: Active	13,735
OVC_SERV_DSD	Program Completion: Graduation	846
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	9,347
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,581

Implementing Mechanism Details

Mechanism ID: 16858	Mechanism Name: Gimbuka
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Caritas Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,403,974	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,403,974	
Funding Source	Funding Amount
GHP-State	1,403,974

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Water	35,000
Adolescent Girls and Young Women (AGYW)	1,001,758

Budget Code Information

Mechanism ID: 16858		
Mechanism Name: Gimbuka		
Prime Partner Name: Caritas Rwanda		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	846,007
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	278,983
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	278,984
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,636
PP_PREV_DSD	Age/sex: 15-19 Male	66
PP_PREV_DSD	Age/sex: 20-24 Male	132
PP_PREV_DSD	Age/sex: 10-14 Female	2,126
PP_PREV_DSD	Age/sex: 15-19 Female	3,248
PP_PREV_DSD	Age/sex: 20-24 Female	998
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,570
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	66
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,927
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,225
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,116
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,329
OVC_SERV_DSD	By: Age/sex: Male 25+	979
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,391
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,743
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,159
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,937
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,475
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,271
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,729
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	148
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,082
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,271



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	3,229
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,926
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,778
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,271
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	3,229
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,926
OVC_SERV_DSD	Age/Sex: <1	6
OVC_SERV_DSD	Age/Sex: 1-9	47
OVC_SERV_DSD	Program Completion: Active	15,287
OVC_SERV_DSD	Program Completion: Graduation	640
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	8,528
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,927

Implementing Mechanism Details

Mechanism ID: 16859	Mechanism Name: Rwanda Social Marketing Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 332,189	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 332,189	
Funding Source	Funding Amount
GHP-State	332,189

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	332,189
---	---------

Budget Code Information

Mechanism ID: 16859		
Mechanism Name: Rwanda Social Marketing Program		
Prime Partner Name: Society for Family Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	332,189
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16860	Mechanism Name: Turengere Abana
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: François Xavier Bagnoud	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,013,039	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,013,039	
Funding Source	Funding Amount
GHP-State	1,013,039

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Adolescent Girls and Young Women (AGYW)	669,102



Water	25,000
-------	--------

Budget Code Information

Mechanism ID: 16860		
Mechanism Name: Turengere Abana		
Prime Partner Name: François Xavier Bagnoud		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	638,033
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	187,502
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	187,504
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a	5,149



	standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 15-19 Male	51
PP_PREV_DSD	Age/sex: 20-24 Male	103
PP_PREV_DSD	Age/sex: 10-14 Female	1,699
PP_PREV_DSD	Age/sex: 15-19 Female	2,575
PP_PREV_DSD	Age/sex: 20-24 Female	721
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,149
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,600
OVC_SERV_DSD	Age/Sex: 10-14 Male	864
OVC_SERV_DSD	Age/Sex: 15-17 Male	300
OVC_SERV_DSD	By: Age/sex: Male 18-24	199
OVC_SERV_DSD	By: Age/sex: Male 25+	1,239
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,737
OVC_SERV_DSD	Age/Sex: 15-17 Female	3,110
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,042
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,271
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,011
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,000
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,150
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	350
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,000
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,900
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	1,100



	and sex: Social Protection Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	750
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	750
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,000
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,900
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,100
OVC_SERV_DSD	Age/Sex: <1	7
OVC_SERV_DSD	Age/Sex: 1-9	1,838
OVC_SERV_DSD	Program Completion: Active	11,460
OVC_SERV_DSD	Program Completion: Graduation	1,140
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	7,856
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,600

Implementing Mechanism Details

Mechanism ID: 17616	Mechanism Name: Twiyubake
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,665,423	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,665,423	



Funding Source	Funding Amount
GHP-State	5,665,423

Cross-Cutting Budget Attribution(s)

Gender: GBV	180,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Water	70,000
Adolescent Girls and Young Women (AGYW)	1,438,206

Budget Code Information

Mechanism ID: 17616		
Mechanism Name: Twiyubake		
Prime Partner Name: CHF International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	4,860,410
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	402,507
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	402,506
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,587
PP_PREV_DSD	Age/sex: 15-19 Male	116
PP_PREV_DSD	Age/sex: 20-24 Male	348
PP_PREV_DSD	Age/sex: 10-14 Female	2,548
PP_PREV_DSD	Age/sex: 15-19 Female	5,908
PP_PREV_DSD	Age/sex: 20-24 Female	2,664
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,584
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	74,493
OVC_SERV_DSD	Age/Sex: 10-14 Male	9,245
OVC_SERV_DSD	Age/Sex: 15-17 Male	9,057
OVC_SERV_DSD	By: Age/sex: Male 18-24	3,514
OVC_SERV_DSD	By: Age/sex: Male 25+	9,565
OVC_SERV_DSD	Age/Sex: 10-14 Female	11,123
OVC_SERV_DSD	Age/Sex: 15-17 Female	6,458
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,598



OVC_SERV_DSD	By: Age/sex: 25+ Female	9,906
OVC_SERV_DSD	Sum of Age/Sex disaggregates	35,883
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,896
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	3,076
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	2,847
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	2,723
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	2,231
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	5,580
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	3,348
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,173
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	501
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,231
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	5,580
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	3,348
OVC_SERV_DSD	Age/Sex: <1	28
OVC_SERV_DSD	Age/Sex: 1-9	12,027
OVC_SERV_DSD	Program Completion: Active	65,555
OVC_SERV_DSD	Program Completion: Graduation	8,938
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	47,938
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR	74,493



	OVC programs for children and families affected by HIV/AIDS	
--	--	--

Implementing Mechanism Details

Mechanism ID: 17618	Mechanism Name: SFH Rwanda
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 496,362	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 496,362	
Funding Source	Funding Amount
GHP-State	496,362

Cross-Cutting Budget Attribution(s)

Gender: GBV	101,375
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Implementation

Budget Code Information

Mechanism ID: 17618
Mechanism Name: SFH Rwanda



Prime Partner Name: Society for Family Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	215,328
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	206,034
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	75,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	60
PrEP_NEW_DSD	Female 15-19	3
PrEP_NEW_DSD	Female 20-24	15
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	15
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	12



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,288
PP_PREV_DSD	Age/sex: 15-19 Male	188
PP_PREV_DSD	Age/sex: 20-24 Male	1,691
PP_PREV_DSD	Age/sex: 50+ Male	64
PP_PREV_DSD	Age/sex: 10-14 Female	63
PP_PREV_DSD	Age/sex: 15-19 Female	313
PP_PREV_DSD	Age/sex: 20-24 Female	689
PP_PREV_DSD	Age/sex: 50+ Female	25
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,033
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	501
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	939
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	438
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	438
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	313
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	313
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	125
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	188
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	600
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,003
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	1,676



	10-14, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,006
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	393
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	658
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	862
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,160
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	435
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	92
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	461
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	33



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	84
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1,440
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,440
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,440
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	63

	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	720
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	720
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	720
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,440
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,440
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	57



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	3
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	550
TX_NEW_TA	By Age/Sex: 10-14 Male	28
TX_NEW_TA	By Age/Sex: 15-19 Male	28
TX_NEW_TA	By Age/Sex: 20-24 Male	48
TX_NEW_TA	By Age/Sex: 50+ Male	20
TX_NEW_TA	By Age/Sex: 10-14 Female	3
TX_NEW_TA	By Age/Sex: 15-19 Female	2
TX_NEW_TA	By Age/Sex: 20-24 Female	12
TX_NEW_TA	By Age/Sex: 50+ Female	43
TX_NEW_TA	Sum of Age/Sex disaggregates	184
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	24
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male,	68



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	67
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	24
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	67
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	24
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	67
HTS_SELF_DSD	HTS_SELF_N_DSD	3,492
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	314
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	175



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	175
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,083
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,409
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	698

Implementing Mechanism Details



Mechanism ID: 17619	Mechanism Name: Implementing Evidence-Based Prevention Intervention for Key Populations in Republic of Rwanda under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,210,561	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,210,561	
Funding Source	Funding Amount
GHP-State	2,210,561

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	623,085
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	444,795
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	17619	
Mechanism Name:	Implementing Evidence-Based Prevention Intervention for Key	
Prime Partner Name:	Populations in Republic of Rwanda under PEPFAR	
	Emory University	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	3,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	58,673
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	734,574
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,156,801
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	257,513
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,000
VMMC_CIRC_DSD	By Age: 10-14	225
VMMC_CIRC_DSD	By Age: 15-19	1,060
VMMC_CIRC_DSD	By Age: 20-24	630
VMMC_CIRC_DSD	By Age: 25-29	410
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,915
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,325
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,100
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	900
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	360
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	270
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	45
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,222
PrEP_NEW_DSD	Female 15-19	61
PrEP_NEW_DSD	Female 20-24	305
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	305
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	244
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	244
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	61
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	29,324
PP_PREV_DSD	Age/sex: 15-19 Male	1,476
PP_PREV_DSD	Age/sex: 20-24 Male	4,426
PP_PREV_DSD	Age/sex: 50+ Male	1,481
PP_PREV_DSD	Age/sex: 15-19 Female	1,476



PP_PREV_DSD	Age/sex: 20-24 Female	4,425
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,284
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,855
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,476
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,855
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,476
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,476
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,950
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,476
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,476
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,038
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,440
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,598
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	55,801
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,765
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	72
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,626
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	11



	15-19, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	7,838
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	160
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,291
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	108
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1,352
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	938
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,440
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	470
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	6
HTC_TST_DSD	By Key Population: FSW, Negative	9,227
HTC_TST_DSD	By Key Population: FSW, Positive	554
HTC_TST_DSD	By Key Population: MSM, Negative	1,401
HTC_TST_DSD	By Key Population: MSM, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	978
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	527
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	5



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	4,530
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	603
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	345
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,703
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,916
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	2,602
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,016
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,960

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	2,066
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,434
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,255
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	666
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	933
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	1,200
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	1,068
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	933
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	34



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	801
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	933
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	801
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	290
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	434
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	300
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	60
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	282
TX_NEW_TA	By Age/Sex: 15-19 Male	3
TX_NEW_TA	By Age/Sex: 20-24 Male	9
TX_NEW_TA	By Age/Sex: 50+ Male	1
TX_NEW_TA	By Age/Sex: 15-19 Female	11
TX_NEW_TA	By Age/Sex: 20-24 Female	55
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	81
TX_NEW_TA	Pregnancy status	2
TX_NEW_TA	Breastfeeding status	1
TX_NEW_TA	FSW	93
TX_NEW_TA	MSM	11



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	28
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	23
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	26
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	26
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	23
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	26
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	23
HTS_SELF_DSD	HTS_SELF_N_DSD	10,931
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	867
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	342
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	430
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29,	109



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	547
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,621
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	7,310
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW,	2,187



	Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	389

Implementing Mechanism Details

Mechanism ID: 17623	Mechanism Name: Strengthening HIV Clinical Services in the Republic of Rwanda under PEPFAR	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Rwanda		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 16,011,222	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 16,011,222	
Funding Source	Funding Amount
GHP-State	16,011,222

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	25,159
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	35,222
Focus Area:	Training of health workers and community outreach



	workers
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	7,724,810
Food and Nutrition: Policy, Tools, and Service Delivery	4,075

Budget Code Information

Mechanism ID:	17623	
Mechanism Name:	Strengthening HIV Clinical Services in the Republic of Rwanda	
Prime Partner Name:	under PEPFAR Ministry of Health, Rwanda	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	542,578
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	542,582
Strategic Area	Budget Code	Planned Amount
Care	PDCS	542,582
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	810,787
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	678,226
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,635,896
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	10,715,989
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	542,582

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,187
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	103,083
PMTCT_ART_DSD	New on ART	705
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,482
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	103,083
PMTCT_STAT_DSD	Number of new ANC and L&D clients	104,134
PMTCT_STAT_DSD	By Age (Denominator): 10-14	72
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,098



PMTCT_STAT_DSD	By Age (Denominator): 20-24	26,656
PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	51
PMTCT_STAT_DSD	By Number of known positives: 20-24	249
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	43
PMTCT_STAT_DSD	By Number of new positives: 20-24	164
PMTCT_STAT_DSD	By Number of new negative: 10-14	15
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,464
PMTCT_STAT_DSD	By Number of new negative: 20-24	25,329
PMTCT_STAT_DSD	By Number of new negative: 50+	4
PMTCT_STAT_DSD	By Age (Numerator): 10-14	17
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,557
PMTCT_STAT_DSD	By Age (Numerator): 20-24	25,729
PMTCT_STAT_DSD	By Age (Numerator): 50+	4
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	18,791
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	17,929
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	17,929
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	17,659
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	550
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	17,592
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	119
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	550
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	17,449
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	111
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	550



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	17,449
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	110
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	550
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	17,321
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	110
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	18,281
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	18,134
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	18,131
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	18,004
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	49,194
VMMC_CIRC_DSD	By Age: 10-14	1,232
VMMC_CIRC_DSD	By Age: 15-19	31,758
VMMC_CIRC_DSD	By Age: 20-24	8,844
VMMC_CIRC_DSD	By Age: 25-29	3,678
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	41,834
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	45,512
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	34,437
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	14,756
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,966
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,477
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	241
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	428
PrEP_NEW_DSD	Male 20-24	21
PrEP_NEW_DSD	Female 15-19	21



PrEP_NEW_DSD	Female 20-24	51
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	77
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	43
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	86
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	43
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	43
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	21
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	950,002
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,393
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,389
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,599
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,247
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	11,799
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,635
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	17



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3,939
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,305
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	558
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,632
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,290
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,326
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	7,024
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	146
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,359
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	90
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1,068
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	620



	50+, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,772
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,907
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	12,198
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	12,299
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	25,717
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	285
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	28,351
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	17,327
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	14,994
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	181



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1,159
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	9,571
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	8,576
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	7



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	23,563
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,875
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,220
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,051
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,421
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,278
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,613



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	323
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	918
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	578
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	452
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	132
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	563
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,551
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	49
HTC_TST_DSD	By Key Population: FSW, Negative	6,937
HTC_TST_DSD	By Key Population: FSW, Positive	371
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	3,217
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	38
HTC_TST_DSD	By Key Population: TG, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,464
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	24,500
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female,	4,526



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	10,392
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	15,384
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	27,195
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	31,978
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	432
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	30,407
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	13,198
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	255
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	13,177
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	259
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	420
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,474



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	4,173
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	101
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	2,249
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	12,696
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	232
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	2,575
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	1,471
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	998
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	836
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	306
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	783
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	291
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34,	767



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	297
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	711
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	271
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	712
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	286
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	692
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	743
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	683
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	5,210
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,978
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	5,320
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	43



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,978
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	5,320
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,978
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	5,320
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	3,063
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,380
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,551
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	2,437
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34,	1,703



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,774
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,703
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,296
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,184
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,328
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	27,935
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	18,818
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	27,935
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	189



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	18,818
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	27,443
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	18,063
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	272
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	26,660
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	210
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	13,276
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	288
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	18,047
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	125
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	18,047
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	17,395
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49,	17,395



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	62
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	8



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	17,795
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	260
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	18,101
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	261
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	18,104
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	267
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	17,952
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	260
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	17,658
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	267
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	18,584
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	261
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	18,584
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	267
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	17,962
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	260
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29,	2,845



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	3,983
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	5,121
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	86
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	4,553
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	3,984
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	3,414
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	3,984
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	3,414
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,455
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	18



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	6,384
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	4,911
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	983
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	7
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,546
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,546
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	73
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	958
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	511
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	62
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases,	952



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	501
GEND_GBV_DSD	Number of people receiving post-GBV care	7,796
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,691
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,097
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	112
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	1,290
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	141
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	122
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	75
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	702
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	129
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	33
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	120
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	2,243
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	53
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	309
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	296
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	33
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	92
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	37
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	178



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	275
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	79
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	178
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	275
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	79
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	178
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	199
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	79
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	137
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	160
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	79
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	9
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	417
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The	4



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	250
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	166
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,190
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,037
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	153
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,190
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	105,429
TX_CURR_DSD	Age/Sex: 15-19 Male	1,553
TX_CURR_DSD	Age/Sex: 15-19 Female	2,030
TX_CURR_DSD	Sum of age/sex disaggregates	3,583
TX_CURR_DSD	Age/Sex: <1	32
TX_CURR_DSD	Age/Sex: <1-9	1,965
TX_CURR_DSD	Age/Sex: 10-14 Male	1,384
TX_CURR_DSD	Age/Sex: 10-14 Female	1,407
TX_CURR_DSD	Age/Sex: 20-24 Male	1,869
TX_CURR_DSD	Age/Sex: 50+ Male	11,275
TX_CURR_DSD	Age/Sex: 20-24 Female	4,616



TX_CURR_DSD	Age/Sex: 50+ Female	13,097
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,846
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	5,681
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	10,846
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,681
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	10,846
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,681
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	10,846
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,681
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,997
TX_CURR_TA	Age/Sex: 15-19 Male	254
TX_CURR_TA	Age/Sex: 15-19 Female	283
TX_CURR_TA	Sum of Age/Sex disaggregations	537
TX_CURR_TA	Age/Sex: 1-9	211
TX_CURR_TA	Age/Sex: 10-14 Male	142
TX_CURR_TA	Age/Sex: 10-14 Female	139
TX_CURR_TA	Age/Sex: 20-24 Male	300
TX_CURR_TA	Age/Sex: 50+ Male	1,601
TX_CURR_TA	Age/Sex: 20-24 Female	687
TX_CURR_TA	Age/Sex: 50+ Female	1,773
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,925
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	958



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,925
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	958
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,925
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	958
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,925
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	958
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,876
TX_NEW_DSD	By Age/Sex: <1	50
TX_NEW_DSD	By Age/Sex: 1-9	89
TX_NEW_DSD	By Age/Sex: 10-14 Male	65
TX_NEW_DSD	By Age/Sex: 15-19 Male	142
TX_NEW_DSD	By Age/Sex: 20-24 Male	535
TX_NEW_DSD	By Age/Sex: 50+ Male	697
TX_NEW_DSD	By Age/Sex: 10-14 Female	185
TX_NEW_DSD	By Age/Sex: 15-19 Female	517
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,467
TX_NEW_DSD	By Age/Sex: 50+ Female	688
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,296
TX_NEW_DSD	Pregnancy status	1,180
TX_NEW_DSD	Breastfeeding status	233
TX_NEW_DSD	FSW	152
TX_NEW_DSD	MSM	4
TX_NEW_DSD	People in prisons and other enclosed settings	184
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,192



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	944
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,192
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	944
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,192
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	940
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,192
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	940
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	249
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	3
TX_NEW_TA	By Age/Sex: 15-19 Male	1
TX_NEW_TA	By Age/Sex: 20-24 Male	6
TX_NEW_TA	By Age/Sex: 50+ Male	2
TX_NEW_TA	By Age/Sex: 10-14 Female	6
TX_NEW_TA	By Age/Sex: 15-19 Female	8
TX_NEW_TA	By Age/Sex: 20-24 Female	44
TX_NEW_TA	By Age/Sex: 50+ Female	3
TX_NEW_TA	Sum of Age/Sex disaggregates	70
TX_NEW_TA	Pregnancy status	18
TX_NEW_TA	FSW	50
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	22
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female,	24



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	21
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	21
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	20
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	22
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	20
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	92,531
TX_PVLS_DSD	Denominator: Indication: Routine	74,024
TX_PVLS_DSD	Denominator: Indication: Targeted	18,505
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	4,631
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,608
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	4,633
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,623
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	18,475
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	18,527
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	18,491
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	18,487
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,251



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,888
TX_RET_DSD	Numerator by Status: Pregnant	718
TX_RET_DSD	Numerator by Status: Breastfeeding	60
TX_RET_DSD	Denominator by Status: Pregnant	808
TX_RET_DSD	Denominator by Status: Breastfeeding	73
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	170
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,440
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	164
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,468
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	175
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,698
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	171



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,820
HTS_SELF_DSD	HTS_SELF_N_DSD	70,038
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	4,641
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	4,616
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,248
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	701
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	701
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	701



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	700
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	701
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	3,502
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	25,628
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	44,410
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	14,007
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	121,758
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,893
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,774
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	73,489
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	42,605
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,827
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	997



	Specimen Sent]: Smear Only	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	836

Implementing Mechanism Details

Mechanism ID: 17625	Mechanism Name: Implementing Technical and Science Support Services (TSSS) in the Republic of Rwanda under PEPFAR	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Rwanda		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 5,389,218	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,389,218	
Funding Source	Funding Amount
GHP-State	5,389,218

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,474,590
----------------------------	-----------

Budget Code Information

Mechanism ID:	17625	
Mechanism Name:	Implementing Technical and Science Support Services (TSSS) in the Republic of Rwanda under PEPFAR	
Prime Partner Name:	Ministry of Health, Rwanda	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	63,053
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	42,035
Strategic Area	Budget Code	Planned Amount
Care	PDCS	143,786
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	345,891
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,431,663
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	275,413
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	210,177



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	274,913
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,368,216
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	84,071

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18418	Mechanism Name: Alliance for Health Communities (AHC)
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Alliance for Health Communities	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,072,017	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,072,017	
Funding Source	Funding Amount
GHP-State	1,072,017

Cross-Cutting Budget Attribution(s)

Gender: GBV	35,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 18418		
Mechanism Name: Alliance for Health Communities (AHC)		
Prime Partner Name: Alliance for Health Communities		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	21,883
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	3,231



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	261,894
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	78,921
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	15,564
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	687,292
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	3,232

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	16
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	665
PMTCT_ART_DSD	New on ART	8
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	665
PMTCT_STAT_DSD	Number of new ANC and L&D clients	665
PMTCT_STAT_DSD	By Age (Denominator): 20-24	89
PMTCT_STAT_DSD	By Number of known positives: 20-24	1
PMTCT_STAT_DSD	By Number of new positives: 20-24	2
PMTCT_STAT_DSD	By Number of new negative: 20-24	89
PMTCT_STAT_DSD	By Age (Numerator): 10-14	1
PMTCT_STAT_DSD	By Age (Numerator): 20-24	91
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	144
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	144
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	144



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	144
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	140
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	140
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	140
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	14
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	140
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	14
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	143
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	143
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,792
VMMC_CIRC_DSD	By Age: 10-14	1,055
VMMC_CIRC_DSD	By Age: 15-19	6,223



VMMC_CIRC_DSD	By Age: 20-24	1,771
VMMC_CIRC_DSD	By Age: 25-29	577
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	9,049
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	9,626
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	8,954
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	3,838
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,689
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,266
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	211
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	90
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	9
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	9
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,508
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	116



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	6,036
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,571
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male,	109



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male,	13



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	16



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	14



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	9



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	2



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male,	16



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	1



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49,	12



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	964
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	834
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	680
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	221
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	221
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	117
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	3



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	117
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	93
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	41
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	17



	TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	30
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	15
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	15
PMTCT_EID_DSD	Sum of Infant Age disaggregates	30
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,709
TX_CURR_DSD	Age/Sex: 15-19 Male	17
TX_CURR_DSD	Age/Sex: 15-19 Female	28
TX_CURR_DSD	Sum of age/sex disaggregates	45
TX_CURR_DSD	Age/Sex: <1-9	27
TX_CURR_DSD	Age/Sex: 10-14 Male	37
TX_CURR_DSD	Age/Sex: 10-14 Female	16
TX_CURR_DSD	Age/Sex: 20-24 Male	349
TX_CURR_DSD	Age/Sex: 50+ Male	59
TX_CURR_DSD	Age/Sex: 20-24 Female	94
TX_CURR_DSD	Age/Sex: 50+ Female	321
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	149
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	539
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	149
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	539
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	149
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	539
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49,	149



	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	539
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	400
TX_NEW_DSD	By Age/Sex: 1-9	1
TX_NEW_DSD	By Age/Sex: 10-14 Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Male	10
TX_NEW_DSD	By Age/Sex: 20-24 Male	44
TX_NEW_DSD	By Age/Sex: 50+ Male	21
TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	27
TX_NEW_DSD	By Age/Sex: 20-24 Female	54
TX_NEW_DSD	By Age/Sex: 50+ Female	37
TX_NEW_DSD	Sum of Age/Sex disaggregates	201
TX_NEW_DSD	Pregnancy status	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	25
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	3,524



	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Denominator: Indication: Routine	2,819
TX_PVLS_DSD	Denominator: Indication: Targeted	705
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	176
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	176
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	176
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	176
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	705
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	705
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	705
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	705
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	538
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	549
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	363
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	19



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	137
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	371
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	140
HTS_SELF_DSD	HTS_SELF_N_DSD	2,500
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	427
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	308
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	427
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	308
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	57



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	426
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	308
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	775
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,725
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,709
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	15
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	31
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,348
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	2,315
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	22
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	22

Implementing Mechanism Details

Mechanism ID: 18422	Mechanism Name: Enhancing Sustainable and Integrated Health, Strategic Information and Laboratory Systems for Quality Comprehensive HIV Services through Technical Assistance to the Republic of Rwanda under PEPFAR
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 714,797	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 714,797	
Funding Source	Funding Amount
GHP-State	714,797

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	18422 Enhancing Sustainable and Integrated Health, Strategic Information and Laboratory Systems for Quality Comprehensive HIV Services through Technical Assistance to the Republic of Rwanda under PEPFAR University of Maryland Baltimore	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	3,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	421,921
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	53,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	232,376
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	3,500

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18426	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 25,427,272	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 25,427,272	
Funding Source	Funding Amount
GHP-State	25,427,272



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18426		
Mechanism Name: Global Health Supply Chain Program		
Prime Partner Name: Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	639,818
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	554,563
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	89,387
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	112,574
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	538,284
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,918,268
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,757,388
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	14,481,300
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,335,690
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 18432	Mechanism Name: Global Health Fellows Program - II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Public Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1	
Funding Source	Funding Amount
GHP-State	1

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18432	
Mechanism Name:	Global Health Fellows Program - II	
Prime Partner Name:	Public Health Institute	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70277	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70278	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70279	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 70280	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70281	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70282	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70283	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70284	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70285	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70286	TBD: Yes
---------------------	----------

Approved



REDACTED

Implementing Mechanism Details

Mechanism ID: 70513	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		154,250		154,250	15,750	170,000
ICASS		506,126		506,126	49,874	556,000
Management Meetings/Professional Development		37,375		37,375	2,625	40,000
Non-ICASS Administrative Costs		466,893		466,893	47,249	514,142
Staff Program Travel		206,200		206,200	21,000	227,200
USG Staff Salaries and Benefits - Internationally Recruited		554,908		554,908	57,749	612,657
USG Staff Salaries and Benefits - Locally Recruited		664,161		664,161	68,249	732,410
Total	0	2,589,913	0	2,589,913	262,496	2,852,409



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		4,000		4,000	0	4,000
ICASS		35,000		35,000	0	35,000
Non-ICASS Administrative Costs		6,000		6,000	0	6,000
Staff Program Travel		70,000		70,000	0	70,000
USG Staff Salaries and Benefits - Locally Recruited		150,000		150,000	0	150,000
Total	0	265,000	0	265,000	0	265,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		896,267		896,267	0	896,267



Computers/IT Services		141,391		141,391	0	141,391
ICASS		1,175,000		1,175,000	0	1,175,000
Institutional Contractors		354,424		354,424	0	354,424
Management Meetings/Professional Development		75,000		75,000	0	75,000
Non-ICASS Administrative Costs		90,493		90,493	0	90,493
Non-ICASS Motor Vehicles		50,000		50,000	0	50,000
Staff Program Travel		369,431		369,431	0	369,431
USG Staff Salaries and Benefits - Internationally Recruited	1,440,625	860,516		2,301,141	0	2,301,141
USG Staff Salaries and Benefits - Locally Recruited	0	1,393,805		1,393,805	0	1,393,805
Total	1,440,625	5,406,327	0	6,846,952	0	6,846,952

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied
-------------------------------	-----	-----------	-----------	----------------------	------------------	---------------------------------------

Approved



						Pipeline Amount
Non-ICASS Administrative Costs		10,000		10,000	0	10,000
Staff Program Travel		35,000		35,000	0	35,000
USG Staff Salaries and Benefits - Internationally Recruited		215,000		215,000	0	215,000
Total	0	260,000	0	260,000	0	260,000